Skip to main content

CORRECTION article

Front. Pharmacol., 30 August 2021
Sec. Experimental Pharmacology and Drug Discovery
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.757060

Corrigendum: 7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth

This article is a correction to:

  1. 7-Ethyl-10-Hydroxycamptothecin, a DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth

    1. Read original article
Airong WangAirong WangLingling LiLingling LiMengya LiMengya LiShujuan WangShujuan WangChong Wang Chong Wang*
  • Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

A corrigendum on
7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth

by Wang, A., Li, L., Li, M., Wang, S., and Wang, C. (2021). Front. Pharmacol. 10:757060. doi: 10.3389/fphar.2021.664176

In the original article, the title was incorrectly written as “Case Report: 7-Ethyl-10-hydroxycamptothecin, a DNA topoisomerase I inhibitor, performs BRD4 inhibitory activity and inhibits human leukemic cell growth”.

The correct article title is “7-Ethyl-10-hydroxycamptothecin, a DNA topoisomerase I inhibitor, performs BRD4 inhibitory activity and inhibits human leukemic cell growth”.

The authors state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: SN-38, BRD4, inhibitor, leukemic cell, growth

Citation: Wang A, Li L, Li M, Wang S and Wang C (2021) Corrigendum: 7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth. Front. Pharmacol. 12:757060. doi: 10.3389/fphar.2021.757060

Received: 11 August 2021; Accepted: 13 August 2021;
Published: 30 August 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Wang, Li, Li, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chong Wang, fccwangc@zzu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.